NCT05550688 is a clinical trial in Nonalcoholic Fatty Liver Disease, sponsored by Ningbo No. 1 Hospital.

Who is sponsoring NCT05550688?

NCT05550688 is sponsored by Ningbo No. 1 Hospital.

What condition does NCT05550688 study?

NCT05550688 studies Nonalcoholic Fatty Liver Disease, Type 2 Diabetes.

Is NCT05550688 still recruiting?

NCT05550688 is currently completed. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT05550688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Weight Gain After Smoking Cessation and NAFLD

Completed Last updated 22 September 2022

What this trial tests

trial in Nonalcoholic Fatty Liver Disease in 12,941 participants. Completed in 1 August 2022.

Timeline

1 January 2007

Primary endpoint
31 December 2014

1 August 2022

Quick facts

Lead sponsor	Ningbo No. 1 Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12,941
Start date	1 January 2007
Primary completion	31 December 2014
Estimated completion	1 August 2022
Sites	1 location across China

Conditions studied

Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →
Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Ningbo No. 1 Hospital

Who can join

18 and older, any sex, with Nonalcoholic Fatty Liver Disease or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce the risk of type 2 diabetes mellitus (T2DM) in patients with NAFLD. Cigarette smoking has a significant negative impact on public health, causing more than 480,000 deaths each year. Smoking has been reported as a risk factor for NAFLD and might accelerate liver disease progression. Therefore, it is recommended that patients with NAFLD quit smoking. However, smoking cessation could be complicated by weight gain. Thus, it is important to assess the impact of weight change after smoking cessation on patients with NAFLD. Proper management of post-cessation weight could maximize its health benefits. In this large-scale cohort study, the investigators aimed to assess the effects of smoking cessation and subsequent weight change on risks of incident T2DM in individuals with NAFLD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Risk of incident type 2 diabetes in male NAFLD and NAFLD-free smokers: a 7-year post-cessation study.
Xie J, Lin P, Hou L, Miao M, et al · · 2024 · cited 1× · PMID 39118126 · DOI 10.1186/s13098-024-01435-4

Verify or expand the search:

Other recruiting trials for Nonalcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT07248371 — Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases · recruiting
NCT07149571 — To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status · recruiting
NCT06368882 — Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty · Phase 4 · recruiting

Other Ningbo No. 1 Hospital trials

Trials by the same sponsor.

NCT07181759 — Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone · NA · not yet recruiting
NCT07001865 — Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia · enrolling by invitation
NCT06984510 — Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population · recruiting
NCT06905795 — Screening and Intervention of MASLD in Children · NA · active not recruiting
NCT06987760 — Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05550688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ningbo No. 1 Hospital
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05550688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing